Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-l...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | EJC Skin Cancer |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611825000060 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199267216621568 |
|---|---|
| author | Sophia Kreft Tommaso Bosetti Rebecca Lee Paul Lorigan |
| author_facet | Sophia Kreft Tommaso Bosetti Rebecca Lee Paul Lorigan |
| author_sort | Sophia Kreft |
| collection | DOAJ |
| description | Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-line treatment for advanced melanoma. Nivolumab-relatlimab has shown greater efficacy compared to single-agent nivolumab and has fewer unacceptable side effects compared to the combination of ipilimumab and nivolumab (ipilimumab-nivolumab). However, the lack of both long-term follow-up data and direct comparison with ipilimumab-nivolumab raises uncertainty about where to position nivolumab-relatlimab in clinical practice. Since most patients who respond to combination ipilimumab-nivolumab also respond to nivolumab-relatlimab, and many to single-agent anti-programmed death-1 (PD-1) monotherapy, the challenge is to identify the subgroup of patients who need ipilimumab-nivolumab and would not achieve similar benefits from less toxic alternatives. This review discusses the available data on efficacy of the three approved first-line immunotherapies (single-agent anti-PD-1, nivolumab-relatlimab or ipilimumab-nivolumab) and their value in distinct population groups to help guide clinical decisions. |
| format | Article |
| id | doaj-art-73a1187139ad4bb985f8a3ed78a12eb0 |
| institution | Kabale University |
| issn | 2772-6118 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-73a1187139ad4bb985f8a3ed78a12eb02025-02-08T05:01:42ZengElsevierEJC Skin Cancer2772-61182025-01-013100285Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populationsSophia Kreft0Tommaso Bosetti1Rebecca Lee2Paul Lorigan3The Christie NHS Foundation Trust, Manchester, United Kingdom; Correspondence to: The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, United Kingdom.The Christie NHS Foundation Trust, Manchester, United KingdomThe Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United KingdomThe Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United KingdomImmunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-line treatment for advanced melanoma. Nivolumab-relatlimab has shown greater efficacy compared to single-agent nivolumab and has fewer unacceptable side effects compared to the combination of ipilimumab and nivolumab (ipilimumab-nivolumab). However, the lack of both long-term follow-up data and direct comparison with ipilimumab-nivolumab raises uncertainty about where to position nivolumab-relatlimab in clinical practice. Since most patients who respond to combination ipilimumab-nivolumab also respond to nivolumab-relatlimab, and many to single-agent anti-programmed death-1 (PD-1) monotherapy, the challenge is to identify the subgroup of patients who need ipilimumab-nivolumab and would not achieve similar benefits from less toxic alternatives. This review discusses the available data on efficacy of the three approved first-line immunotherapies (single-agent anti-PD-1, nivolumab-relatlimab or ipilimumab-nivolumab) and their value in distinct population groups to help guide clinical decisions.http://www.sciencedirect.com/science/article/pii/S2772611825000060MelanomaImmune checkpoint inhibitorsFirst-line treatmentTreatment selection |
| spellingShingle | Sophia Kreft Tommaso Bosetti Rebecca Lee Paul Lorigan Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations EJC Skin Cancer Melanoma Immune checkpoint inhibitors First-line treatment Treatment selection |
| title | Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations |
| title_full | Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations |
| title_fullStr | Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations |
| title_full_unstemmed | Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations |
| title_short | Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations |
| title_sort | selecting first line immunotherapy in advanced melanoma current evidence on efficacy across diverse patient populations |
| topic | Melanoma Immune checkpoint inhibitors First-line treatment Treatment selection |
| url | http://www.sciencedirect.com/science/article/pii/S2772611825000060 |
| work_keys_str_mv | AT sophiakreft selectingfirstlineimmunotherapyinadvancedmelanomacurrentevidenceonefficacyacrossdiversepatientpopulations AT tommasobosetti selectingfirstlineimmunotherapyinadvancedmelanomacurrentevidenceonefficacyacrossdiversepatientpopulations AT rebeccalee selectingfirstlineimmunotherapyinadvancedmelanomacurrentevidenceonefficacyacrossdiversepatientpopulations AT paullorigan selectingfirstlineimmunotherapyinadvancedmelanomacurrentevidenceonefficacyacrossdiversepatientpopulations |